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Individuals with the rare genetic disorder Werner 
syndrome (WS) show the premature onset of 
many of the clinical features of old age, with early 
susceptibility to several major age-related diseases 
and a shortened median life expectancy (47 years). 
Mutation in the WRN gene [1,2] results in acceler-
ated in vivo aging and premature senescence of 
cells in vitro that may underlie several features 
of WS clinical pathophysiology [3–5]. Senescent 
cells display deleterious bio chemical features 
and a proinflammatory phenotype, suggesting 
a link between replicative senescence and tissue 
degeneration [6,7]. Unlike normal human fibrob-
lasts, proliferating WS cells contain high levels of 
phosphorylated p38a, a stress-activated mitogen-
activated protein kinase (MAPK), suggesting 
that WS cells undergo premature senescence by 
a telomere-independent mechanism [8–10], which 
synergizes with telomere-erosion processes [11]. 
The treatment of WS cells with the p38 inhibi-
tor SB203580 resulted in the rescue of all of the 
features of accelerated replicative decline, includ-
ing the short replicative lifespan, slow growth rate 
and altered cell morphology [8], indicating that 
the abbreviated life span of WS cells is linked to 
a stress-induced growth arrest mediated by p38a 
MAPK. If accelerated aging in WS is related to 
p38 activation and to accelerated cell aging, WS 
may provide a powerful model system to link cel-
lular signaling events to the aging of mitotic tissues 
in vivo [12] and, thus, provides the opportunity for 
therapeutic intervention in the pathology of WS.
Given the poor kinase selectivity profile of 
the prototypical inhibitor SB203580, as well as 
reported toxicity issues, we set out to prepare 
a number of other p38a inhibitor chemotypes 
(FiguRe 1) for study in WS cells. Our recent 
reports on successful routes to BIRB 796 [13], 
VX-745 [14,15], UR-13756 [16] and RO3201195 [17] 
have all utilized microwave dielectric heating to 
accelerate access to compounds for study and have 
resulted in dramatic improvements in both the 
facility and efficiency of synthetic routes. The use 
of microwave irradiation has received increasing 
attention in recent years as a valuable alternative 
to the use of conductive heating for accelerating 
transformations in synthetic chemistry, medici-
nal chemistry and the biosciences [18–24]. In our 
recent route to RO3201195 (FiguRe 1D) [17], we 
demonstrated that microwave irradiation can 
facilitate the rapid synthesis of a pyrazolyl ketone 
building block for elaboration to the target inhibi-
tor, which exhibits oral bioavailability and high 
selectivity for p38 over other kinases [25]. This 
central motif contains the key pharmacophore 
of the chemotype, with a unique hydrogen bond 
between an exocyclic N and Thr-106 in the 
ATP-binding pocket.
This manuscript describes experimental proce-
dures for the rapid synthesis of a small library of 
pyrazolyl ketones and a key intermediate in the 
synthesis of RO3201195 and evaluates a series of 
related compounds for comparison in WS cells. 
Previous studies have indicated that meta-substi-
tution of the benzoyl group is preferred, offering 
greater tolerability to a wide range of substituents, 
as well as being a facile point of installation for 
a solubilizing group, such as the 2,3-dihydroxy-
propoxy function in RO3201195. Preliminary 
structural–activity relationship (SAR) studies 
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on the N-phenyl function of this chemotype, 
on the other hand, indicated that only small 
hydrophobic groups were tolerated and that para-
substitution with relatively less polar groups gave 
rise to higher activities. Keeping the core pharma-
cophore intact (exocyclic amine, benzoyl group 
and pyrazole), we set out to establish whether the 
trends in library activity described in the original 
report were also in evidence in WS cells. In so 
doing, it was hoped that it would also be pos-
sible to explore how the size of the substituted 
N-phenyl moiety influenced the activity for a 
series of compounds bearing functionality that 
could be readily converted to the solubilizing 
dihydroxypropoxy group.
Experimental section
 General procedures
Commercially available reagents were used with-
out further purification; solvents were dried by 
standard procedures. Light petroleum refers to the 
fraction with boiling point (bp) 40–60°C. Flash 
chromatography was carried out using Merck 
Kieselgel 60 H silica or Matrex silica 60. Analytical 
thin layer chromatography was carried out using 
aluminium-backed plates coated with Merck 
Kieselgel 60 GF254 that were visualized under 
UV light (at 254 and/or 360 nm). Microwave 
irradiation experiments were performed using a 
self-tunable CEM Discover-focused monomodal 
microwave synthesizer at the given temperature, 
measured using the instrument’s in-built IR sen-
sor, by varying the irradiation power (initial power 
given in parentheses). Fully characterized com-
pounds were chromatographically homogeneous. 
Melting points were determined on a Kofler hot 
stage apparatus and are uncorrected. IR spectra 
were recorded on a Perkin–Elmer 1600 series 
Fourier transform (FT)IR spectrometer in the 
range 4000–600 cm-1 using KBr disks for solid 
samples and thin films between NaCl plates for 
liquid samples or as a nujol mull and are reported 
in cm-1. NMR spectra were recorded using a 
Bruker DPX 400 instrument or 500 Avance 
instrument operating at 400 MHz for 1H spectra 
and 100 or 125 MHz for 13C spectra in CDCl
3
 at 
25°C unless stated otherwise and were reported in 
ppm; J values were recorded in Hz and multiplici-
ties were expressed by the usual conventions. Low-
resolution mass spectra were determined using a 
Fisons VG Platform II Quadrupole instrument 
using atmospheric pressure chemical ionization 
(APcI) unless stated otherwise as electrospray ioni-
zation (ES), chemical ionization ([CI], ammonia) 
or electron ionization (EI). In vacuo refers to evap-
oration at reduced pressure using a rotary evapora-
tor and diaphragm pump, followed by the removal 
of trace volatiles using a vacuum (oil) pump.
 General procedure for the 
microwave-assisted synthesis of 
aminoacrylonitriles 2
A solution of benzoylacetonitrile 1B (0.10 g, 
0.69 mmol) and N,N´-diphenylformamidine 
(0.135 g, 0.69 mmol) in dry xylenes (0.5 ml) 
was irradiated in a sealed tube at 180°C for 
30 min using a CEM Discover single-mode 
microwave synthesizer, by moderating the 
initial microwave power (100 W). After cool-
ing in a stream of compressed air, the mix-
ture was diluted with Et
2
O. The precipitate 
was filtered and washed with Et
2
O to give 
aminoacrylonitrile 2B.
2- (3-methoxybenzoyl) -3-phenylamino-
acrylonitri le (2A) [R
f
 = 0.46 (l ight 
petroleum:EtOAc, 4:1)] was obtained as a 
colourless solid [25] mp 105°C (Et
2
O) (found: 
MH+, 279.1129. C
17
H
15
N
2
O
2
 [MH+] requires 
279.1128); IR (KBr) n
max
 3063, 3012, 2961, 
2840, 1637, 1598, 1574, 1489, 1394, 1372, 1316, 
1270, 1226, 1045, 991, 869, 832, 742, 683; 1H 
NMR (400 MHz, CDCl
3
) d 12.75 (1H, d, J 13.0, 
NH), 8.06 (1H, d, J 13.0 Hz), 7.55 (1H, d, J 7.4), 
7.47–7.36 (4H), 7.28 (1H, t, J 7.2), 7.21 (2H, d, J 
8.0), 7.09 (1H, d, J 8.4), 3.86 (3H, s); 13C NMR 
(100 MHz, CDCl
3
) d 192.2 (C), 159.5 (C), 
154.1 (CH), 139.1 (C), 138.0 (C), 130.2 (CH), 
129.5 (CH), 126.7 (CH), 120.5 (CH), 120.4 
(C), 118.9 (CH), 117.9 (CH), 112.5 (CH), 83.4 
(C), 55.5 (CH
3
); m/z (APcI) 279 (MH+, 90%).
Figure 1. Microwave irradiation has been used to accelerate the synthesis 
of a number of p38 MAPK inhibitors, including (A) BIRB 796 [13]; 
(B) VX-745 [14,15]; (C) UR-13756 [16] and (D) RO3201195 [17].
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2-benzoyl-3-phenylaminoacrylonitrile (2B) 
[R
f
 = 0.47 (light petroleum:EtOAc, 7:3)] was 
obtained as a colourless solid [25] melting point 
(mp) 158–159°C (light petroleum) (found: 
MH+, 249.1022. C
16
H
13
N
2
O [MH+] requires 
249.1022); IR (KBr) n
max
 3185, 2361, 2205, 
1697, 1665, 1606, 1577, 1559, 1542, 1474, 
1422, 1396, 1314, 1269, 1145, 1076, 992, 924; 
1H NMR (400 MHz, CDCl
3
) d 12.70 (1H, br s, 
NH), 8.08–8.03 (1H, m, CH), 7.95–7.90 (2H, 
m), 7.58–7.41 (5H), 7.31–7.10 (3H); 13C NMR 
(100 MHz, CDCl
3
) d 192.5 (C), 154.1 (CH), 
138.0 (C), 132.3 (CH), 130.2 (CH), 129.7 (C), 
128.4 (CH), 128.0 (CH), 126.7 (CH), 120.5 
(C), 117.8 (CH), 117.9 (CH), 83.3 (C); m/z 
(APcI) 249 (MH+, 100%).
 General procedure for the  
microwave-assisted synthesis of  
pyrazolyl ketones 4A–X
A mixture of 3-methoxy-2-benzoyl-3-phenyl-
aminoacrylonitrile (2A) or 2-benzoyl-3-phenyl-
aminoacrylonitrile (2B) (0.108 mmol, 1 equiv-
alent) and the hydrazine 3A-P (0.108 mmol, 
1 equivalent), in the presence or absence of 
Et
3
N (0.12 mmol, 1.1 equivalent), in ethanol 
(1.23 ml) was irradiated in a sealed tube at 
140°C (measured using the in-built IR sensor) 
for 1 h using a CEM Discover single-mode 
microwave synthesizer, by moderating the 
initial microwave power (100 W). After cool-
ing in a stream of compressed air, the mixture 
was concentrated and evaporated in vacuo. 
Purification by column chromatography on 
SiO
2
 gel, eluting with light petroleum:EtOAc, 
gave the desired pyrazole.
[5-amino-1-(4-iodophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4A) [R
f
 = 0.48 
(light petroleum:EtOAc, 3:2)] was obtained 
as a colorless solid (22.6 mg, 75%), mp 142°C 
(light petroleum) (found: MH+, 420.0207. 
C
17
H
15
N
3
O
2
I [MH+] requires 420.0203); IR 
(KBr) n
max
 3366, 3242, 3171, 2955, 1615, 1595, 
1582, 1539, 1488, 1430, 1396, 1323, 1308, 
1282, 1246, 1210, 1145, 1040, 1007, 938, 843, 
817, 770, 684, 639, 613, 562; 1H NMR (400 
MHz, CDCl
3
): d 7.87–7.85 (2H, m), 7.81 (1H, s, 
3 -´H), 7.42–7.38 (2H, m), 7.36–7.31 (3H), 7.11–
7.08 (1H, m, 4-H), 6.10 (2H, br s, NH
2
), 3.87 
(3H, s, OMe); 13C NMR (100 MHz, CDCl
3
) 
d 189.5 (C), 159.7 (C), 150.5 (C), 142.4 (CH), 
140.9 (C), 139.0 (CH), 136.9 (C), 129.6 (CH), 
125.5 (CH), 120.7 (CH), 117.9 (CH), 112.8 
(CH), 105.0 (C), 93.4 (C), 55.5 (CH
3
); m/z 
(ES) 420 (MH+, 100%).
[5-amino-1-(4-f luorophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4B) [R
f
 =
 
0.57 
(light petroleum:EtOAc, 3:2)] was obtained as 
a colorless solid (19 mg, 86%) [25] mp 114°C 
(light petroleum) (found: MH+, 312.1143. 
C
17
H
15
N
3
O
2
F [MH+] requires 312.1143); IR 
(KBr) n
max
 3437, 3292, 2923, 1636, 1614, 1596, 
1575, 1539, 1496, 1451, 1398, 1308, 1286, 1241, 
1223, 1158, 1051, 929, 838, 759,678, 619; 1H 
NMR (400 MHz, CDCl
3
) d 7.82 (1H, s, 3 -´H), 
7.59–7.55 (2H, m), 7.44–7.43 (2H, m), 7.36–
7.35 (1H, m), 7.29–7.24 (2H, m), 7.14–7.11 
(1H, m), 6.07 (2H, br s, NH
2
), 3.90 (3H, s, 
OCH
3
); 13C NMR (100 MHz, CDCl
3
) d 189.5 
(C), 162.1 (d, 1J
C-F
 248.0, C), 159.7 (C), 150.5 
(C), 142.0 (CH), 140.9 (C), 133.1 (d, 4J
C-F
 3.3, 
C), 129.5 (CH), 126.1 (d, 3J
C-F
 8.8, CH), 120.6 
(CH), 117.8 (CH), 116.9 (d, 2J
C-F
 23.0, CH), 
112.9 (CH), 104.8 (C), 55.4 (CH
3
); m/z (APcI) 
312 (MH+, 100%).
[5-amino-1-(4-f luorophenyl)-1H-pyrazol-
4-yl] phenyl ketone (4C) [R
f
 = 0.7 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
colorless solid (17.2 mg, 76%) [25] mp 164°C 
(light petroleum) (found: MH+, 281.0957. 
C
16
H
13
N
3
OF [MH+] requires 281.0964); IR 
(KBr) n
max 
3447, 3315, 3067, 2923, 1633, 1614, 
1594, 1541, 1516, 1485, 1442, 1402, 1307, 1228, 
1156, 1020, 904, 875, 842, 822, 754, 733, 689, 
619, 590; 1H NMR (400 MHz, CDCl
3
) d 7.84–
7.80 (2H, m), 7.78 (1H, s, 3 -´H), 7.59–7.47 (5H), 
7.27–7.20 (2H, m), 6.05 (2H, br s, NH
2
); 13C 
NMR (100 MHz, CDCl
3
) d 189.8 (C), 162.1 
(d, 1J
C-F
 250.6, C), 150.5 (C), 142.1 (CH), 139.7 
(C), 133.2 (d, 4J
C-F
 3.3, C), 131.6 (CH), 128.6 
(CH), 128.2 (CH), 126.2 (d, 3J
C-F
 8.4, CH), 
116.9 (d, 2J
C-F
 23.1, CH), 104.8 (C); m/z (EI) 
204 (MH+, 30%), 280 (100).
[5-amino-1-(4-bromophenyl)-1H-pyrazol-
4-yl] phenyl ketone (4D) [R
f
 = 0.75 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
colorless solid (17.3 mg, 63%), mp 147–150°C 
(light petroleum) (found: MH+, 342.0242. 
C
16
H
13
N
3
O79Br [MH+] requires 342.0242); IR 
(KBr) n
max
 3369, 3242, 3171, 1612, 1537, 1493, 
1396, 1306, 1279, 1210, 1007, 904, 840, 822, 
765, 734, 695, 671, 613, 527; 1H NMR (400 
MHz, CDCl
3
) d 7.87 (2H, d, J 8.8), 7.82–7.78 
(3H), 7.49–7.59 (3H), 7.34 (2H, d, J 8.8), 
6.10 (2H, br s, NH
2
); 13C NMR (100 MHz, 
CDCl
3
) d 189.8 (C), 150.4 (C), 142.4 (CH), 
139.6 (C), 139.1 (CH), 137.0 (C), 131.6 (CH), 
128.6 (CH), 128.0 (CH), 125.5 (CH), 122.0 
(C), 105.0 (C); m/z (ES) 344 (C
16
H
13
N
3
O81Br+, 
90%), 342 (C
16
H
13
N
3
O79Br+, 100).
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[5-amino-1-(2,6-dichlorophenyl)-1H-pyr-
azol-4-yl] phenyl ketone (4E) [R
f
 = 0.37 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
colourless solid (22.4 mg, 84%) [25], mp 220°C 
(light petroleum) (found: MH+, 332.0342. 
C
16
H
12
N
3
O35Cl
2
 [MH+] requires 332.0357); IR 
(KBr) n
max 
3393, 3257, 3169, 1622, 1568, 1539, 
1507, 1446, 1388, 1309, 1274, 1213, 1161, 1075, 
899, 788, 743, 700, 674, 540, 524; 1H NMR (400 
MHz, CDCl
3
) d 7.90 (1H, s, 3 -´CH), 7.87–7.84 
(2H, m), 7.56–7.49 (5H), 7.46–7.41 (1H, m), 5.86 
(2H, br s, NH
2
); 13C NMR (100 MHz, CDCl
3
) 
d 189.7 (C), 151.9 (C), 142.9 (CH), 139.6 (C), 
135.8 (C), 135.7 (C), 132.0 (CH), 131.6 (CH), 
129.2 (CH), 128.5 (CH), 128.3 (CH), 104.0 
(C); m/z (ES) 334 (C
16
H
12
N
3
O37Cl35Cl+, 70), 
332 (C
16
H
12
N
3
O35Cl
2
+, 100).
[5-amino-1-(2,4-dif luorophenyl)-1H-pyr-
azol-4-yl] phenyl ketone (4F) [R
f
 = 0.5 (light 
petroleum:EtOAc, 3:2)] was obtained as a color-
less solid (15.4 mg, 64%), mp 153°C (light petro-
leum) (found: MH+, 299.0865. C
16
H
12
N
3
OF
2
 
[MH+] requires 299.0870); IR (KBr) n
max 
3392, 
3248, 3166, 2923, 1624, 1602, 1546, 1515, 1502, 
1441, 1403, 1320, 1272, 1146, 1118, 1076, 974, 
954, 903, 876, 853, 800, 759, 734, 701, 619, 565; 
1H NMR (400 MHz, CDCl
3
) d 7.85–7.80 (3H), 
7.58–7.48 (4H), 7.04–7.11 (2H, m), 6.02 (2H, br 
s, NH
2
); 13C NMR (100 MHz, CDCl
3
) d 189.6 
(C), 163.0 (dd, 1J
C-F
 254.7, 3J
C-F
 10.3, C), 156.9 
(dd, 1J
C-F
 255.4, 3J
C-F
 12.0, C), 151.8 (C), 142.8 
(CH), 139.6 (C), 131.6 (CH), 129.9 (dd, 3J
C-F
 
10.2, 1.4, CH), 128.6 (CH), 128.2 (CH), 120.9 
(dd, 2J
C-F
 12.4, 4J
C-F
 4.0, C), 112.8 (dd, 2J
C-F
 22.6, 
4J
C-F
 3.6, CH), 105.6 (dd, 2J
C-F
 27.1, 23.0, CH), 
104.3 (C); m/z (EI) 298 (MH+, 100%), 222 (30).
[5-amino-1-(pentafluorophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4G) [R
f
 = 0.66 
(light petroleum:EtOAc, 3:2)] was obtained as 
a colorless solid (21.5 mg, 78%), mp 180–181°C 
(light petroleum) (found: MH+, 384.0761. 
C
17
H
11
N
3
O
2
F
5
 [MH+] requires 384.0766); IR 
(KBr) n
max
 3428, 3333, 2942, 1633, 1541, 1514, 
1487, 1461, 1426, 1321, 1307, 1255, 1217, 1139, 
1066, 1034, 991, 928, 848, 816, 792, 770; 1H 
NMR (400 MHz, CDCl
3
) d 7.90 (1H, s, 3 -´H), 
7.42–7.41 (2H, m), 7.32 (1H, s, 2-H), 7.13–7.10 
(1H, m, 4-H), 6.30 (2H, br s, NH
2
), 3.88 (3H, s, 
CH
3
); 13C NMR (125 MHz, CDCl
3
) d 189.3 
(C), 159.8 (C), 152.8 (C), 144.1 (app d, 1J
C-F
 
255.0, C), 144.0 (CH), 140.7 (app d, 1J
C-F
 216.0, 
C), 140.5 (C), 138.2 (app d, 1J
C-F
 247.0, C), 
129.6 (CH), 120.6 (CH), 118.9 (CH), 112.9 
(CH), 111.8 (m, C), 104.2 (C), 55.5 (CH
3
); m/z 
(APcI) 384 (MH+, 100%).
(5-amino-1-phenyl-1H-pyrazol-4-yl) phenyl 
ketone (4H) [R
f
 = 0.45 (light petroleum:EtOAc, 
3:2)] was obtained as a colorless solid (40 mg, 
95%) [25] mp 153°C (light petroleum) (found: 
MH+, 264.1133. C
16
H
14
N
3
O [MH+] requires 
264.1131); IR (KBr) n
max
 3200, 2911, 2681, 2520, 
2359, 1614, 1505, 1401, 1309, 1240, 1170, 1118, 
906, 767, 732; 1H NMR (400 MHz, CDCl
3
) d 
7.70–7.60 (3H), 7.45–7.20 (8H), 5.90 (2H); 13C 
NMR (100 MHz, CDCl
3
) d 189.9 (C), 150.4 
(C), 142.0 (CH), 139.8 (C), 137.1 (C), 131.5 
(CH), 130.0 (CH), 128.5 (CH), 128.4 (CH), 
128.2 (CH), 124.0 (CH), 104.8 (C); m/z (APcI) 
264 (MH+, 100%).
[5-amino-1- (4-tolyl) -1H-pyrazol-4-yl] 
3-methoxyphenyl ketone (4I) [R
f
 = 0.57 (light 
petroleum:EtOAc, 3:2)] was obtained as a color-
less solid (32 mg, 58%), mp 165°C (light petro-
leum) (found: MH+, 308.1394. C
18
H
18
N
3
O
2
 
[MH+] requires 308.1394); IR (KBr) n
max
 3381, 
3254, 2961, 2917, 2853, 1614, 1572, 1543, 1502, 
1483, 1429, 1311, 1285, 1247, 1053, 935, 811, 
769, 708; 1H NMR (400 MHz, CDCl
3
) d 7.79 
(1H, s, 3 -´H), 7.45–7.40 (4H), 7.37–7.32 (3H), 
7.11–7.08 (1H, m, 4-H), 6.04 (2H, br s, NH
2
), 
3.87 (3H, s, OCH
3
), 2.43 (3H, s, CH
3
); 13C 
NMR (100 MHz, CDCl
3
) d 189.4 (C), 159.7 
(C), 150.4 (C), 141.9 (CH), 141.1 (C), 138.7 
(C), 134.5 (C), 130.5 (CH), 129.5 (CH), 124.0 
(CH), 120.7 (CH), 117.8 (CH), 112.8 (CH), 
104.7(C), 55.5 (CH
3
), 21.2 (CH
3
); m/z (APcI) 
308 (MH+, 100%).
(5 -amino-1-methyl-1H -py ra zol- 4 -y l ) 
3-methoxyphenyl ketone (4J) [R
f
 = 0.6 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
colorless solid (46%) (found: MH+, 213.0899. 
C
12
H
14
N
3
O
2
 [MH+] 213.0902); IR (KBr) n
max
 
3178, 3158, 2955, 2917, 2884, 2840, 1602, 1583, 
1506, 1471, 1458, 1432, 1288, 1257, 1211, 1096, 
1053, 1029, 957, 874, 851, 776, 714, 687; 1H 
NMR (400 MHz, CDCl
3
) d 7.85 (1H, s, 3 -´CH), 
7.55 (1H, d, J 7.8, 6-H), 7.50 (1H, s, 2-H), 7.37 
(1H, t, J 7.8, 5-H), 6.98–6.95 (1H, m, 4-H), 6.10 
(2H, br s, NH
2
), 4.00 (3H, s, OCH
3
), 3.87 (3H, 
s, CH
3
); 13C NMR (100 MHz, CDCl
3
) d 189.6 
(C), 160.0 (C), 153.2 (C), 141.0 (CH), 136.7 
(C), 130.0 (CH), 119.0 (CH), 115.8 (CH), 114.5 
(C), 111.3 (CH), 55.4 (CH
3
), 39.8 (CH
3
); m/z 
(EI) 213 (MH+, 100%).
[5-amino-1-(4-chlorophenyl)-1H-pyrazol-
4-yl] phenyl ketone (4K) [R
f
 = 0.54 (light 
petroleum:EtOAc, 3:2)] was obtained as a color-
less solid (9.4 mg, 39%), mp 168°C (light petro-
leum) (found: MH+, 298.0732. C
16
H
13
N
3
O35Cl 
[MH+] requires 298.0747); IR (KBr) n
max 
3379, 
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3253, 3060, 2923, 1615, 1598, 1539, 1498, 1395, 
1307, 1279, 1211, 1096, 1012, 903, 845, 823, 802, 
741, 732, 700, 679, 523; 1H NMR (400 MHz, 
CDCl
3
) d 7.83–7.78 (3H), 7.59–7.48 (7H), 6.10 
(2H, br s, NH
2
); 13C NMR (100 MHz, CDCl
3
) 
d 189.8 (C), 150.5 (C), 142.3 (CH), 139.6 (C), 
135.7 (C), 134.2 (C), 131.6 (CH), 130.2 (CH), 
128.6 (CH), 128.2 (CH), 125.2 (CH), 104.9 
(C); m/z (ES) 300 (C
16
H
13
N
3
O37Cl+, 30%), 298 
(C
16
H
13
N
3
O35Cl+, 100).
5-amino-1-(4-chlorophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4L) [R
f
 = 0.7 
(light petroleum:EtOAc, 3:2)] was obtained as 
a colorless solid (13.5 mg, 57%), mp 129–130°C 
(light petroleum) (found: MH+, 328.0868. 
C
17
H
15
N
3
O
2
35Cl [MH+] requires 328.0853); IR 
(KBr) n
max 
3367, 3249, 3171, 2995, 2834, 1614, 
1575, 1540, 1497, 1483, 1454, 1433, 1307, 
1287, 1248, 1210, 1095, 1052, 1012, 934, 846, 
811, 769, 706, 683, 613; 1H NMR (400 MHz, 
CDCl
3
) d 7.80 (1H, s, 3 -´H), 7.53–7.50 (4H), 
7.42–7.40 (2H, m), 7.33 (1H, s, 2-H), 7.12–
7.07 (1H, m, 4-H), 6.09 (2H, br s, NH
2
), 3.87 
(3H, s, CH
3
); 13C NMR (100 MHz, CDCl
3
) d 
189.5 (C), 159.7 (C), 150.5 (C), 142.3 (CH), 
140.9 (C), 135.7 (C), 134.2 (C), 130.2 (CH), 
129.5 (CH), 125.1 (CH), 120.7 (CH), 117.9 
(CH), 112.5 (CH), 104.9 (C), 55.5 (CH
3
); 
m/z (APcI) 330 (C
17
H
15
N
3
O
2
37Cl+, 30%), 328 
(C
17
H
15
N
3
O
2
35Cl+, 100).
[5-amino-1-(2,4-dif luorophenyl)-1H-pyr-
azol-4-yl] 3-methoxyphenyl ketone (4M) [R
f
 = 
0.46 (light petroleum:EtOAc, 3:2)] was obtained 
as a colorless solid (26.6 mg, >98%), mp 90°C 
(light petroleum) (found: MH+, 330.1048. 
C
17
H
14
N
3
O
2
F
2
 [MH+] requires 330.1049); IR 
(KBr) n
max 
3459, 3408, 3323, 3069, 2923, 1633, 
1624, 1611, 1575, 1541, 1493, 1436, 1400, 
1311, 1263, 1248, 1225, 1145, 1110, 1033, 961, 
923, 855, 811, 760, 601; 1H NMR (400 MHz, 
CDCl
3
) d 7.85 (1H, s, 3 -´H), 7.58–7.51 (1H, m), 
7.42–7.40 (2H, m), 7.32 (1H, m, 2-H), 7.11–7.04 
(3H), 6.00 (2H, br s, NH
2
), 3.88 (3H, s, CH
3
); 
13C NMR (100 MHz, CDCl
3
) d 189.4 (C), 
163.0 (dd, 1J
C-F
 253.5, 3J
C-F
 10.9, C), 159.7 (C), 
157.0 (dd, 1J
C-F
 256.8, 3J
C-F
 13.1, C), 151.8 (C), 
142.9 (CH), 140.9 (C), 129.9 (dd, 3J
C-F
 10.2, 4J
C-F
 
1.4, CH), 129.1 (CH), 120.9 (dd, 2J
C-F
 12.0, 4J
C-F
 
3.6, C), 120.7 (CH), 118.0 (CH), 112.8 (dd, 
2J
C-F
 23.0, 4J 4.0, CH), 112.7 (CH), 105.6 (dd, 
2J
C-F
 26.3, 23.0, CH), 104.3 (C), 55.5 (CH
3
); 
m/z (APcI) 330 (MH+, 100%).
[5-amino-1-(2-f luorophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4N) [R
f
 = 0.36 
(light petroleum:EtOAc, 3:2)] was obtained as 
a colorless solid (10 mg, 90%), mp 133–134°C 
(light petroleum) (found: MH+, 312.1137. 
C
17
H
15
N
3
O
2
F [MH+] requires 312.1143); IR 
(KBr) n
max 
3356, 3261, 3178, 3051, 3005, 2968, 
1627, 1612, 1581, 1545, 1510, 1458, 1397, 1294, 
1243, 1054, 976, 871, 834, 774, 686; 1H NMR 
(400 MHz, CDCl
3
) d 8.06 (1H, s, 3 -´H), 7.48–
7.40 (3H), 7.29–7.23 (1H, m), 7.15–6.91 (2H, 
m), 6.90–6.45 (4H), 3.70 (3H, s, CH
3
); 13C 
NMR (100 MHz, CDCl
3
) d 189.6 (C), 159.6 
(C), 156.4 (d, 1J
C-F
 254.0, C), 149.4 (C), 143.4 
(CH), 135.8 (C), 131.4 (d, 3J
C-F
 7.7, CH), 130.2 
(d, 3J
C-F
 7.6, CH), 128.7 (CH), 126.8 (d, 2J
C-F
 
11.7, C), 125.1 (d, 4J
C-F
 4.0, CH), 120.7 (CH), 
116.9 (d, 2J
C-F
 = 19.4 Hz, CH), 116.4 (CH), 
113.8 (CH), 93.2 (C), 55.3 (CH
3
); m/z (ES) 
312 (MH+, 100%).
[5-amino-1-(2,5-dichlorophenyl)-1H-pyr-
azol-4-yl] 3-methoxyphenyl ketone (4O) [R
f
 = 
0.53 (light petroleum:EtOAc, 3:2)] was obtained 
as a colorless oil (23.3 mg, 78%); IR (KBr) n
max 
3406, 3287, 3178, 2961, 2917, 1622, 1578, 1536, 
1480, 1429, 1373, 1307, 1285, 1251, 1209, 1094, 
1039, 926, 875, 819, 766, 730, 580; 1H NMR 
(400 MHz, CDCl
3
) d 7.85 (1H, s, 3 -´H), 7.55–
7.52 (2H, m), 7.47–7.44 (1H, m), 7.43–7.40 (2H, 
m), 7.34 (1H, s, 2-H), 7.12–7.07 (1H, m, 4-H), 
5.95 (2H, br s, NH
2
), 3.88 (3H, s, CH
3
); 13C 
NMR (100 MHz, CDCl
3
) d 189.4 (C), 159.7 
(C), 151.7 (C), 142.7 (CH), 140.9 (C), 135.1 
(C), 133.8 (C), 131.7 (CH), 131.4 (CH), 130.4 
(C), 130.0 (CH), 129.6 (CH), 120.7 (CH), 
117.9 (CH), 112.8 (CH), 104.1 (C), 55.5 (CH
3
).
[5-amino-1-(2,6-dichlorophenyl)-1H-pyr-
azol-4-yl] 3-methoxyphenyl ketone (4P) [R
f
 = 
0.3 (light petroleum:EtOAc, 3:2)] was obtained 
as a colorless oil (5.8 mg, 45%) (found: MH+, 
362.0460. C
17
H
14
N
3
O
2
35Cl
2
 [MH+] requires 
362.0458); IR (KBr) n
max 
3408, 3283, 3184, 
2961, 2936, 1623, 1575, 1538, 1503, 1439, 
1387, 1308, 1285, 1241, 1200, 1041, 926, 
814, 793, 732, 642; 1H NMR (400 MHz, 
CDCl
3
) d 7.90 (1H, s, 3 -´H), 7.54–7.50 (2H, 
m), 7.46–7.40 (3H), 7.35 (1H, s, 2-H), 7.11–
7.07 (1H, m, 4-H), 5.88 (2H, br s, NH
2
), 3.88 
(3H, s, CH
3
); 13C NMR (100 MHz, CDCl
3
) d 
189.3 (C), 159.7 (C), 152.0 (C), 142.8 (CH), 
140.9 (C), 135.8 (C), 135.7 (C), 132.0 (CH), 
129.5 (CH), 129.2 (CH), 120.7 (CH), 117.9 
(CH), 112.8 (CH), 104.0 (C), 55.5 (CH
3
); m/z 
(ES) 364 (C
17
H
14
N
3
O
2
37Cl35Cl+, 30%), 362 
(C
17
H
14
N
3
O
2
35Cl
2
+, 50).
[5-amino-1-(4-bromophenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4Q) [R
f
 = 0.63 
(light petroleum:EtOAc, 3:2)] was obtained as 
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a colorless solid (24.4 mg, 92%), mp 125–126°C 
(light petroleum) (found: MH+, 372.0339. 
C
17
H
15
N
3
O
2
79Br [MH+] requires 372.0342); 
IR (KBr) n
max 
3369, 3242, 3171, 2955, 1614, 
1582, 1541, 1490, 1461, 1426, 1397, 1324, 
1308, 1280, 1245, 1210, 1146, 1039, 937, 874, 
845, 821, 799, 770, 732, 613, 544; 1H NMR 
(400 MHz, CDCl
3
) d 7.82 (1H, s, 3 -´H), 7.67 
(2H, d, J 8.8), 7.47 (2H, d, J 8.8), 7.42–7.40 
(2H, m), 7.34–7.32 (1H, m, 2-H), 7.12–7.07 (1H, 
m, 4-H), 6.09 (2H, br s, NH
2
), 3.88 (3H, s, 
CH
3
); 13C NMR (100 MHz, CDCl
3
) d 189.5 
(C), 159.7 (C), 150.5 (C), 142.4 (CH), 140.9 
(C), 136.2 (C), 133.1 (CH), 129.6 (CH), 
125.4 (CH), 122.1 (C), 120.7 (CH), 118.0 
(CH), 112.8 (CH), 105.0 (C), 55.5 (CH
3
); 
m/z (ES) 374 (C
17
H
15
N
3
O
2
81Br+, 40%), 372 
(C
17
H
15
N
3
O
2
79Br+, 35), 105 (100).
[5-amino-1-(pentaf luorophenyl)-1H-pyr-
azol-4-yl] phenyl ketone (4R) [R
f
 = 0.74 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
colorless solid (25 mg, 89%), mp 130–135°C 
(light petroleum) (found: MH+, 354.0663. 
C
16
H
9
N
3
OF
5
 [MH+] requires 354.0666); IR 
(KBr) n
max 
3413, 3381, 3298, 3184, 2923, 1621, 
1605, 1544, 1505, 1480, 1432, 1393, 1306, 
1223, 1162, 1114, 1073, 993, 899, 846, 802, 738, 
724, 700, 675, 578, 527; 1H NMR (400 MHz, 
CDCl
3
) d 7.89 (1H, s, 3 -´H), 7.81–7.78 (2H, m), 
7.60–7.55 (1H, m), 7.54–7.48 (2H, m), 6.13 (2H, 
br s, NH
2
); 13C NMR (100 MHz, CDCl
3
) d 
189.6 (C), 152.8(C), 144.1 (app d, 1J
C-F
 257.9, 
C), 144.0 (CH), 139.1 (C), 138.3 (app d, 1J
C-F
 
254.3, C), 138.2 (app d, 1J
C-F
 259.8, C), 131.9 
(CH), 128.6 (CH), 128.4 (CH), 128.1 (CH), 
128.0 (CH), 111.8 (m, C), 104.1 (C); m/z (ES) 
354 (MH+, 100%).
[5-amino-1-(2-f luorophenyl)-1H-pyrazol-
4-yl] phenyl ketone (4S) [R
f
 = 0.46 (light 
petroleum:EtOAc, 3:2)] was obtained as a col-
orless solid (1.8 mg, 8%), mp 162°C (light petro-
leum) (found: MH+, 281.0964. C
16
H
13
N
3
OF 
[MH+] requires 281.0964); IR (KBr) n
max
 3398, 
3249, 3162, 2923, 1623, 1574, 1547, 1505, 1459, 
1402, 1313, 1264, 1228, 1212, 1126, 902, 877, 
820, 770, 757, 741, 703, 635, 610, 549, 523; 1H 
NMR (400 MHz, CDCl
3
) d 7.86–7.80 (3H), 
7.59–7.46 (5H), 7.36–7.28 (2H, m), 6.04 (2H, 
br s, NH
2
); 13C NMR (100 MHz, CDCl
3
) d 
189.6 (C), 156.4 (d, 1J
C-F
 251.7, C), 151.7 (C), 
142.8 (CH), 139.7 (C), 131.6 (CH), 131.1 (d, 
3J
C-F
 8.1, CH), 128.6 (d, 3J
C-F
 10.2, CH), 128.5 
(CH), 128.2 (CH), 125.5 (d, 4J
C-F
 3.7, CH), 
124.2 (d, 2J
C-F
 12.1, C), 117.2 (d, 2J
C-F
 19.4, CH), 
104.4 (C); m/z (EI) 280 (MH+, 100%).
[5-amino-1-(2,5-dichlorophenyl)-1H-pyr-
azol-4-yl] 3-phenyl ketone (4T) [R
f
 = 0.76 (light 
petroleum:EtOAc, 3:2)] was obtained as a color-
less solid (25.3 mg, 95%), mp 154°C (light petro-
leum) (found: MH+, 332.0342. C
16
H
12
N
3
O35Cl
2
 
[MH+] requires 332.0357); IR (KBr) n
max 
3395, 
3266, 3190, 2923, 1621, 1539, 1506, 1480, 1414, 
1375, 1310, 1285, 1247, 1211, 1098, 1075, 1031, 
971, 901, 878, 816, 752, 737, 701, 614, 578; 1H 
NMR (400 MHz, CDCl
3
) d 7.85–7.80 (3H), 
7.59–7.56 (5H), 7.47–7.42 (1H, m), 5.90 (2H, 
br s, NH
2
); 13C NMR (100 MHz, CDCl
3
) d 
189.6 (C), 151.7 (C), 142.7 (CH), 139.6 (C), 
135.1 (C), 133.8 (C), 131.7 (CH), 131.6 (CH), 
131.4 (C), 130.0 (CH), 129.3 (CH), 128.6 
(CH), 128.2 (CH), 105.0 (C); m/z (APcI) 332 
(MH+, 100%).
[5-amino-1-(4-iodophenyl)-1H-pyrazol-
4-yl] 3-phenyl ketone (4U) [R
f
 = 0.6 (light 
petroleum:EtOAc, 3:2)] was obtained as a col-
orless solid (1.4 mg, 5%), mp 170°C (light petro-
leum) (found: MH+, 390.0093. C
16
H
13
N
3
OI 
[MH+] requires 390.0103); IR (KBr) n
max 
3380, 
3261, 3058, 2920, 2853, 1614, 1598, 1573, 1539, 
1495, 1444, 1398, 1306, 1276, 1210, 1072, 
1010, 904, 843, 822, 735, 698, 675, 614, 527, 
507; 1H NMR (400 MHz, CDCl
3
) d 7.83–7.80 
(3H), 7.68 (2H, d, J 8.8), 7.57–7.50 (3H), 
7.47 (2H, d, J 8.8), 6.10 (2H, br s, NH
2
); 13C 
NMR (100 MHz, CDCl
3
) d 189.3 (C), 150.0 
(C), 142.4 (CH), 139.6 (C), 136.0 (C), 133.1 
(CH), 131.6 (CH), 128.5 (CH), 128.2 (CH), 
125.4 (CH), 104.9 (C), 90.6 (C);
 
m/z (ES) 390 
(MH+, 100%).
[5-amino-1-(4-methoxyphenyl)-1H-pyrazol-
4-yl] 3-methoxyphenyl ketone (4V) [R
f
 = 0.38 
(light petroleum:EtOAc, 3:2)] was obtained as 
a colorless solid (4.1 mg, 71%), mp 137°C (light 
petroleum) (found: MH+, 324.1343. C
18
H
18
N
3
O
3
 
[MH+] requires 324.1339); IR (KBr) n
max 
3383, 
3253, 3176, 2957, 2924, 2848, 1614, 1581, 1541, 
1504, 1462, 1397, 1310, 1249, 1029, 935, 838, 
769; 1H NMR (400 MHz, CDCl
3
) d 7.78 (1H, 
s, 3 -´H), 7.46 (2H, d, J 9.0), 7.42–7.38 (2H, m), 
7.36–7.32 (1H, m), 7.11–7.07 (1H, m), 7.04 (2H, 
d, J
 
9.0), 5.60 (2H, br s, NH
2
), 3.87 (3H, s, 
CH
3
), 3.86 (3H, s, CH
3
); 13C NMR (125 MHz, 
CDCl
3
) d 189.3 (C), 159.7 (C), 159.6 (C), 150.6 
(C), 141.7 (CH), 141.2 (C), 129.9 (C), 129.5 
(CH), 125.9 (CH), 120.7 (CH), 117.8 (CH), 
115.1 (CH), 112.9 (CH), 104.7 (C), 55.6 (CH
3
), 
55.4 (CH
3
); m/z (APcI) 324 (MH+, 100%).
(5-amino-1-tert-butyl-1H-pyrazol-4-yl) 
3-methoxyphenyl ketone (4W) [R
f 
 = 0.54 (light 
petroleum:EtOAc, 3:2)] was obtained as a 
R1
O
CN
R1
O
CN
NHPh
R1
O
R2NHNH2 (3A–P)
N
N
R2H2N
1A (R1 = OMe)
1B (R1 = H)
Xylenes, microwaves
180°C , 20–30 min
(71–90%)
NPh
H NHPh
2A (R1 = OMe)
2B (R1 = H)
EtOH, microwave
140 °C , 1 h
( 5 to >98%)
4A–X 
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colorless solid (4.0 mg, 82%), mp 93°C (light 
petroleum) (found: MH+, 274.1549. C
15
H
20
N
3
O
2
 
[MH+] requires 274.1550); IR (KBr) n
max 
3386, 
3292, 2982, 2923, 1598, 1576, 1530, 1496, 1459, 
1317, 1288, 1247, 1218, 1044, 923, 834, 764, 
685; 1H NMR (400 MHz, CDCl
3
) d 7.57 (1H, 
s, 3 -´H), 7.42–7.31 (2H, m), 7.30–7.27 (1H, m, 
2-H), 7.08–7.04 (1H, m, 4-H), 6.10 (2H, br s, 
NH
2
), 3.85 (3H, s, OCH
3
), 1.67 (9H, s, CMe
3
); 
13C NMR (100 MHz, CDCl
3
) d 189.0 (C), 159.0 
(C), 150.6 (C), 139.5 (CH), 136.0 (C), 129.4 
(CH), 120.7 (CH), 117.7 (CH), 112.6 (CH), 
105.8 (C), 55.5 (C), 55.4 (CH
3
), 28.9 (CH
3
); 
m/z (ES) 274 (MH+, 100%), 259 (70), 218 (60).
[5-amino-1-(4-nitrophenyl)-1H-pyrazol-4-yl] 
3-methoxyphenyl ketone (4X) [R
f
 = 0.5 (light 
petroleum:EtOAc, 3:2)] was obtained as a color-
less solid (2.5 mg, 41%), mp 190–191°C (light 
petroleum) (found: MH+, 339.1086. C
17
H
15
N
4
O
4
 
[MH+] requires 339.1088); IR (KBr) n
max
 3450, 
3304, 3066, 2936, 1636, 1613, 1575, 1538, 1524, 
1486, 1450, 1347, 1308, 1290, 1055, 928, 855, 
755; 1H NMR (400 MHz, CDCl
3
) d 8.41 (2H, d, 
J 8.8), 7.88 (1H, s, 3 -´H), 7.84 (2H, d, J 8.8), 7.45–
7.37 (2H, m), 7.33 (1H, s, 2-H), 7.14–7.08 (1H, m, 
4-H), 6.30 (2H, br s, NH
2
), 3.88 (3H, s, CH
3
); 
13C NMR (100 MHz, CDCl
3
) d 189.6 (C), 159.8 
(C), 150.9 (C), 146.4 (C), 143.3 (CH), 142.7 (C), 
140.7 (C), 129.7 (CH), 125.5 (CH), 123.2 (CH), 
120.6 (CH), 118.0 (CH), 112.9 (CH), 105.4 (C), 
55.5 (CH
3
); m/z (ES) 339 (MH+, 100%).
 Determination of the ability of the 
pyrazolyl ketone library to inhibit p38
The ability of the members of the pyrazolyl 
ketone library to inhibit the p38 stress-signaling 
pathway was tested in human telomerase reverse 
trancriptase (hTERT)-immortalized HCA2 
dermal cells, as described previously, using an 
ELISA system (Cell Signaling, NEB, UK) [14]. 
Cells were seeded in 100-mm dishes in Earle’s 
modification of Eagle medium (EMEM) and 
incubated at 37°C for 48 h. The medium was 
supplemented with a solution of the pyra zolyl 
ketone 4 in dimethyl sulfoxide (DMSO) at final 
concentrations of 150 nM and 1.50 µM, and the 
cells incubated for a further 2 h. Then aniso-
mycin was added to the medium at 30 µM and 
the cells harvested 45 min later. Samples using 
DMSO only and DMSO plus anisomycin were 
used as controls. Cells were harvested, proteins 
isolated and the ELISAs carried out according 
to the manufacturer’s instructions. Kinase activ-
ity was detected using antibodies specific for the 
phosphorylated form of the small heat shock 
protein (HSP27) and antibodies that detect the 
total levels of HSP27, the degree of activation 
being measured as the ratio of phosphoprotein/
total protein. In this system, activation of p38 by 
anisomycin activates MAPK-activated kinase 2 
(MK2) that then phosphorylates the HSP27. 
As MK2 is the major HSP27 kinase, the activ-
ity of p38 can be assessed by the phosphoryla-
tion status of HSP27 [26]. The concentrations of 
150 nM and 1.5 µM were chosen because the IC
50
 
for RO32901195 in this system was previously 
determined at approximately 190 nM [17] and we 
were interested in compounds that may be more 
efficacious than the lead compound RO3201195.
The ability of several of the pyrazolyl ketones 
to inhibit the p38 signaling pathway in WS cells 
was tested by preincubation with the selected 
compound at 1.5 µM at 37°C for 2 h, as described 
for HCA2 cells (see above). In this system, the 
p38 pathway is induced by treatment of WS cells 
with anisomycin and p38 activation is detected 
using antibodies specific for the activated (phos-
phorylated) forms of HSP27 immobilized on 
Western blots. Cells were harvested and proteins 
isolated, separated on polyacrylamide gels and 
immunoblotted as described previously [8]. In 
addition, the samples were quantified using an 
ELISA system as described above.
Results & discussion
Fol lowing our microwave-med iated 
route (FiguRe 2), two benzoylacetonitriles 1A 
and 1B, the former readily available from methyl 
4-methoxybenzoate by reaction with acetonitrile 
under basic conditions [27], were reacted with 
N,N´–diphenylformamidine in a microwave-
assisted Knoevenagel condensation reaction at 
Figure 2. Microwave-assisted synthesis of pyrazolyl ketone library 4A–X.
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180°C to give the two β-aminovinyl ketone pre-
cursors [28] 2A & B in good yield after 20–30 min. 
Heterocyclocondensation was then effected, also 
under microwave dielectric heating, by irradiat-
ing 2A & B with a range of hydrazines 3A–P in 
ethanol at 140°C in the presence or absence of 
Et
3
N (depending upon whether the hydrazine 
was obtained as the free base or HCl salt) to give 
a 24-membered pyrazolyl ketone library 4A–X 
(table 1). The efficiency of this reaction proved 
variable, in particular when using benzoylac-
rylonitrile 2B, although difficulties in isolation 
of the pure product could not be ruled out as 
the overriding factor, especially when consid-
ering the small scale. Gratifyingly, reactions of 
(3-methoxybenzoyl)acrylonitrile 2A were much 
more predictable in terms of the isolated yield 
and all of the reactions investigated gave the 
desired product, following chromatographic 
purification on silica.
Biological evaluation of the library was car-
ried out by testing the effects of preincubation 
of human HCA2 dermal fibroblasts with library 
members prior to induction of the p38 signal-
ing pathway by treatment with anisomycin. The 
degree of inhibition was analyzed using an ELISA 
system (see methods) (FiguRe 3) at two different 
concentrations (150 nM and 1.5 µM) and the 
results compared with inhibition by the known 
pyrazolyl ketone RO3201195 (ROCHE). For 
the most part, pyrazolyl ketone library members 
inhibited the anisomycin-induced activation of 
the p38 pathway in human hTERT-immortalized 
HCA2 dermal cells. Of particular interest was 
the role of the N-aryl moiety R2, identified as an 
important group in previous SAR studies using 
enzyme in vitro assays and lipopolysaccharide 
(LPS)-stimulated peripheral blood mononuclear 
cell-based assays [25]. Comparing the activity of 4C 
(R2 = 4-fluorophenyl) and 4H (R2 = phenyl) against 
anisomycin-induced p38 activation (FiguRe 3), it 
was clear that the para-substituted fluorophenyl 
moiety was important – a finding supported 
by previous data [25]. Of the pyrazolyl ketones 
examined, a number of the library members dis-
played activity that compared favourably with, 
or even exceeded, that of RO3201195, includ-
ing two N-(4-fluorophenyl)pyrazoles, 4B & C, 
the N-(2,4-difluorophenyl)pyrazole 4F and the 
N-methylpyrazole 4J. RO3201195 contains an 
additional diol solubilizing group that, although 
it might cause some minor reduction in potency, 
enhances important physical properties includ-
ing its bioavailability and pharmacokinetic profile 
and, so, the discovery of more potent inhibitors, 
while welcome, was not altogether surprising. 
From our library, two of the compounds, 
4C & H, had been evaluated previously [25] for 
enzyme inhibition of p38 MAPK and on assay 
for inhibition of TNFa biosynthesis in THP-1 
cells and the same activity order for these inhibi-
tors was observed in our system. In accordance 
with previous findings, as the size of the N-aryl 
group increased, from 4-fluorophenyl (4B & C) to 
4-chlorophenyl (4K & L), 4-bromophenyl (4D) and 
4-iodophenyl (4A), the activity sharply declined. 
This phenomenon was also felt to be responsible 
for the poor activity of dichloride 4E, pentafluoride 
4G and tolyl 4I. It was unexpected that the inhibi-
tor bearing a N-methyl group 4J would be the most 
potent, but it could be anticipated that such a gain 
would be outweighed by a dramatic reduction in 
kinase selectivity (not tested). What was most 
gratifying was that, for the most part, the incor-
poration of a 3-methoxybenzoyl moiety caused 
no loss in potency with respect to the unsubsti-
tuted analogue (compare 4B & C and 4K & L), 
providing means for subsequent introduction of a 
Table 1. Efficiency of the microwave-assisted synthesis of pyrazolyl 
ketones 4A–X.
Entry 2 R1 3 R2 4 Yield 
(%)*
1 2A MeO 3A 4-iodophenyl 4A 75
2 2A MeO 3B‡ 4-fluorophenyl 4B 86
3 2B H 3B‡ 4-fluorophenyl 4C 76
4 2B H 3C‡ 4-bromophenyl 4D 63
5 2B H 3D‡ 2,6-dichlorophenyl 4E 84
6 2B H 3E‡ 2,4-difluorophenyl 4F 64
7 2A MeO 3F Pentafluorophenyl 4G 78
8 2B H 3G Phenyl 4H 95
9 2A MeO 3H‡ 4-tolyl 4I 58
10 2A MeO 3I Me 4J 46
11 2B H 3J‡ 4-chlorophenyl 4K 39
12 2A MeO 3J‡ 4-chlorophenyl 4L 57
13 2A MeO 3E‡ 2,4-difluorophenyl 4M >98
14 2A MeO 3K‡ 2-fluorophenyl 4N 90
15 2A MeO 3L 2,5-dichlorophenyl 4O 78
16 2A MeO 3D‡ 2,6-dichlorophenyl 4P 45
17 2A MeO 3C‡ 4-bromophenyl 4Q 92
18 2B H 3F pentafluorophenyl 4R 89
19 2B H 3K‡ 2-fluorophenyl 4S 8
20 2B H 3M 2,5-dichlorophenyl 4T 95
21 2B H 3A 4-iodophenyl 4U 5
22 2A MeO 3N‡ 4-methoxyphenyl 4V 71
23 2A MeO 3O‡ t-butyl 4W 82
24 2A MeO 3P 4-nitrophenyl 4X 41
*Refers to isolated yield after purification by column chromatography. 
‡Et
3
N (1.1 equivalent) was added to the reaction mixture in order to liberate the hydrazine free base.
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solubilizing group. It was also unexpected that the 
2,4-difluorophenyl-substituted analogue 4F would 
have an improved activity profile over the 4-fluoro-
phenyl compound 4C. Although this phenomenon 
has been observed before in the enzyme activity of 
two similarly substituted pyrazolyl ketones [25], it 
apparently has not been pursued further.
The most effective of the pyrazolyl ketones in 
HCA2 cells were tested for their efficacy to inhibit 
p38 in WS cells by immunoblot detection of 
activated HSP27 (FiguRe 4). In control WS cells, 
there was a low level of pHSP27 that was greatly 
increased by anisomycin treatment. The most 
effective inhibitors in HCA2 cells were equally as 
effective as inhibitors in WS cells, with difluoride 
4F again being the most effective and 4E used as 
a negative control, as it showed little inhibition 
in HCA2 cells. As these are different cell systems 
(HCA2 are neonatal foreskin dermal cells while 
WS cells are adult dermal skin cells) that have 
different growth and morphological character-
istics [9,10], and two different assay systems have 
been used, these data indicate a high degree of 
biological reproducibility. Interestingly, however, 
RO3201195 appears to exhibit a slight increase in 
potency in WS cells than in HCA2 cells.
Conclusion
In conclusion, a library of pyrazolyl ketones 
can be prepared rapidly in essentially a two-
step process using microwave dielectric heat-
ing for evaluation as inhibitors of p38 MAPK 
signal transduction in WS cells. On biological 
evaluation, a number of inhibitors demonstrated 
similar, if not improved, potency in cell-based 
ELISA assays over RO2101195. Some SAR, in 
particular regarding the pyrazole N-aryl moiety, 
have been confirmed and promising candidates 
were evaluated further in WS cells, where a 
slight increase in activity may well be evident for 
RO3201195. Given the ease and speed of forma-
tion of these pyrazolyl ketones using microwave 
dielectric heating and their activity in WS cells, 
this library would appear to be ideal for further 
study to rescue premature senescence and the 
accelerated aging of WS cells in culture and cor-
relate these observations with p38 activity. These 
studies are now underway in our laboratories and 
will be reported in due course.
Future perspective
Microwave dielectric heating has found widespread 
acceptance as an important means to accelerate 
chemical reactions. Nowhere has this been more 
prolific than in medicinal chemistry, where safe, 
effective, rapid, reliable and efficient processes are 
vital in order to accelerate and facilitate the drug-
discovery process. There are many reaction types 
Figure 3. Inhibition of p38 MAPK by pyrazolyl ketones 4A–L and 
comparison with RO3201195 as shown by ELISA. Only the ratio of 
phosphorylated HSP27 to total HSP27 is indicated. A are cells treated with 
anisomycin, ROCHE are cells pretreated for 2 h with RO3201195 followed by 
treatment with anisomycin and 4A–L are cells pretreated for 2 h with compounds 
4A–L followed by treatment with anisomycin. Dark bars are pyrazolyl ketones at 
150 nM and lighter bars are pyrazolyl ketones at 1.5 µM.
Figure 4. Effects of selected pyrazolyl ketones on the activity of p38 in 
WS cells. Top panels are immunoblots probed with antibodies for pHSP27 and 
HSP27. Bottom panel is an ELISA showing the ratio of pHSP27/HSP27 using the 
same samples for quantification.
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that are highly suitable for investigation under 
microwave irradiation: transition metal-mediated 
processes, S
N
Ar reactions and heterocycle-forming 
processes, typified by the heterocyclocondensation 
reaction for pyrazole formation described in this 
report, being just a select few. The facility to oper-
ate under sealed-tube conditions above the boiling 
point of the solvent can simplify and accelerate 
chemical transformations and provides the means 
to carry out the synthesis of chemical libraries in 
an incredibly short time, especially when using an 
automated system. It is our expectation that the 
coming 5–10 years will see many more reports 
on the use and development of this technology, 
establishing its place as the principal synthetic tool 
of the medicinal chemist.
Acknowledgements
We thank the EPSRC Mass Spectrometry Service at the 
University of Wales, Swansea, UK, for mass spectra. 
Ethical conduct of research 
The authors state that they have obtained appropriate insti-
tutional review board approval or have followed the princi-
ples outlined in the Declaration of Helsinki for all human 
or animal experimental investigations. In addition, for 
investi gations involving human subjects, informed consent 
has been obtained from the participants involved.
Financial & competing interests disclosure
The authors thank the BBSRC (BB/D524140), EPSRC 
(GR/S25456) and SPARC (awards to Terence Davis and 
Mark Bagley) for support of this work. The authors have 
no other relevant affiliations or financial involvement with 
any organization or entity with a financial interest in or 
financial conflict with the subject matter or materials discussed 
in the manuscript. This includes employment, consultancies, 
honoraria, stock ownership or options, expert t estimony, grants 
or patents received or pending, or royalties.
No writing assistance was utilized in the production of 
this manuscript.
Executive summary
 Microwave irradiation promotes both Knoevenagel condensation and heterocyclocondensation in the rapid synthesis of a 24-membered 
pyrazolyl ketone library.
 For the most part, pyrazolyl ketones inhibited the anisomycin-induced activation of the p38 pathway in human hTERT-immortalized 
HCA2 dermal cells.
 Structure–activity relationships indicated that large N-aryl groups were not tolerated by the p38 enzyme, in agreement with known data, 
whereas the addition of a 3-methoxy substituent in the benzoyl group caused no appreciable loss in activity.
 Four pyrazolyl ketones displayed activity, which compared favorably with, or even exceeded, that of RO3201195, with particular promise 
shown by a N-(2,4-difluorophenyl) analogue.
 The potency of promising pyrazolyl ketones was confirmed in WS cells, where a slight increase in activity may well be evident 
for RO3201195.
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